Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine plus Rituximab without Autologous Transplant

被引：8

作者：

Hill, Brian T. ^{[1
]}

Switchenko, Jeffrey M. ^{[2
]}

Martin, Peter ^{[3
]}

Churnetski, Michael C. ^{[4
]}

Sawalha, Yazeed ^{[5
]}

Goyal, Subir ^{[2
]}

Shanmugasundaram, Krithika ^{[6
]}

Calzada, Oscar ^{[7
]}

Kolla, Bhaskar ^{[8
]}

Bachanova, Veronika ^{[8
]}

Gerson, James N. ^{[9
]}

Barta, Stefan K. ^{[9
]}

Gordon, Max J. ^{[10
]}

Danilov, Alexey ^{[11
]}

Grover, Natalie S. ^{[12
]}

Mathews, Stephanie ^{[13
]}

Burkart, Madelyn ^{[14
,15
]}

Karmali, Reem ^{[16
]}

Ghosh, Nilanjan ^{[17
]}

Park, Steven I. ^{[18
]}

Epperla, Narendranath ^{[19
]}

Bond, David A. ^{[20
]}

Badar, Talha ^{[21
]}

Blum, Kristie A. ^{[22
]}

Guo, Jin ^{[23
]}

Hamadani, Mehdi ^{[24
]}

Fenske, Timothy S. ^{[25
]}

Malecek, Mary-Kate ^{[26
]}

Kahl, Brad S. ^{[26
]}

Flowers, Christopher R. ^{[27
]}

Cohen, Jonathon B. ^{[28
]}

机构：

[1] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA

[2] Emory Univ, Winship Canc Inst, Biostat & Bioinformat, Atlanta, GA 30322 USA

[3] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA

[4] Emory Univ, Winship Canc Inst, Ctr Med, Atlanta, GA 30322 USA

[5] Cleveland Clin, Taussig Canc Inst, Dept Med & Hematol Oncol, Cleveland, OH 44106 USA

[6] Emory Univ, Sch Med, Atlanta, GA USA

[7] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[8] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[9] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[12] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[13] Univ N Carolina, Chapel Hill, NC 27515 USA

[14] Northwestern Univ, Chicago, IL 60611 USA

[15] Northwestern Hosp, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[16] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[17] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[18] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[19] Marshfield Clin Fdn Med Res & Educ, Columbus, OH USA

[20] Ohio State Univ Hosp, James Canc Ctr, Columbus, OH 43210 USA

[21] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[23] Weill Cornell Med, Dept Med, New York, NY USA

[24] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[25] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA

[26] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[27] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[28] Emory Univ, Atlanta, GA 30322 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-129404

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1525

引用

页数：6

共 50 条

[1] Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Merryman, Reid W.
Edwin, Natasha
Redd, Robert
Bsat, Jad
Chase, Matthew
LaCasce, Ann
Freedman, Arnold
Jacobson, Caron
Fisher, David
Ng, Samuel
Crombie, Jennifer
Kim, Austin
Odejide, Oreofe
Davids, Matthew S.
Brown, Jennifer R.
Jacene, Heather
Cashen, Amanda
Bartlett, Nancy L.
Mehta-Shah, Neha
Ghobadi, Armin
Kahl, Brad
Joyce, Robin
Armand, Philippe
Jacobsen, Eric
BLOOD ADVANCES, 2020, 4 (05) : 858 - 867
[2] Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma
Villa, Diego
Sehn, Laurie H.
Savage, Kerry J.
Toze, Cynthia L.
Song, Kevin
den Brok, Wendie L.
Freeman, Ciara L.
Scott, David W.
Gerrie, Alina S.
BLOOD, 2019, 134
[3] Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma
Villa, Diego
Sehn, Laurie H.
Savage, Kerry J.
Toze, Cynthia L.
Song, Kevin
den Brok, Wendie D.
Freeman, Ciara L.
Scott, David W.
Gerrie, Alina S.
BLOOD ADVANCES, 2020, 4 (15) : 3486 - 3494
[4] A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP plus /- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma
Wang, Hui
Xing, Lijie
Liu, Dan
Wei, Haichen
Lu, Ke
He, Qiang
Xie, Linna
Ma, Ji
Qiu, Lugui
Li, Zengjun
BLOOD, 2024, 144 : 6307 - 6308
[5] Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma
Graf, Solomon A.
Stevenson, Philip A.
Holmberg, Leona A.
Till, Brian G.
Press, Oliver W.
Chauncey, Thomas R.
Smith, Stephen D.
Philip, Mary
Orozco, Johnnie J.
Shustov, Andrei R.
Green, Damian J.
Libby, Edward N.
Bensinger, William I.
Pagel, John M.
Maloney, David G.
Zhou, Yi
Cassaday, Ryan D.
Gopal, Ajay K.
BLOOD, 2014, 124 (21)
[6] Outcomes of Rituximab and Bendamustine Induction Regimen VS Cytarabine-Based Induction for Patients with Mantle Cell Lymphoma
Alnimer, Yanal
Yalniz, Fevzi
Monohan, Gregory
Munker, Reinhold
Qasrawi, Ayman
Iragavarapu, Chait
Amr, Mahmoud
BLOOD, 2024, 144 : 6320 - 6321
[7] A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
Dreyling, Martin
Tam, Constantine S.
Wang, Michael
Smith, Stephen D.
Ladetto, Marco
Huang, Huiqiang
Novotny, William
Co, Melannie
Romano, Alfredo
Holmgren, Eric
Huang, Jane
Le Gouill, Steven
FUTURE ONCOLOGY, 2021, 17 (03) : 255 - 262
[8] Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Wang, Michael L.
Jurczak, Wojciech
Jerkeman, Mats
Trotman, Judith
Zinzani, Pier L.
Belada, David
Boccomini, Carola
Flinn, Ian W.
Giri, Pratyush
Goy, Andre
Hamlin, Paul A.
Hermine, Olivier
Hernandez-Rivas, Jose-Angel
Hong, Xiaonan
Kim, Seok Jin
Lewis, David
Mishima, Yuko
Ozcan, Muhit
Perini, Guilherme F.
Pocock, Christopher
Song, Yuqin
Spurgeon, Stephen E.
Storring, John M.
Walewski, Jan
Zhu, Jun
Qin, Rui
Henninger, Todd
Deshpande, Sanjay
Howes, Angela
Le Gouill, Steven
Dreyling, Martin
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (26): : 2482 - 2494
[9] In vivo purging with hyper-CVAD plus rituximab followed by autologous stem cell transplant and rituximab maintenance in newly diagnosed mantle cell lymphoma
Benedetti, E
Caracciolo, F
Papineschi, F
Galimberti, S
Pelosini, M
Castiglioni, M
Mechelli, S
Scatena, P
Petrini, M
BONE MARROW TRANSPLANTATION, 2005, 35 : S240 - S240
[10] Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
Wang, Yucai
Larson, Melissa C.
Kumar, Anita
Hill, Brian T.
Bond, David Alan
Kahl, Brad S.
Danilov, Alexey Valeryevich
Merryman, Reid
Grover, Natalie Sophia
Tun, Aung M.
Ayyappan, Sabarish Ram
Pongas, Georgios
Portell, Craig Anthony
Munoz, Javier
Reagan, Patrick Michael
Moustafa, Muhamad Alhaj
Pophali, Priyanka Avinash
Greenwell, Irl Brian
Cohen, Jonathon Brett
Martin, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →